In the News

This Journal of Oncology article highlights recent, innovative changes that are occurring in oncology clinical trial development.

Andrew Garrett discusses challenges such as patient recruitment for biotechs developing therapies for targeted populations with rare diseases.

Chuhua Wu outlines the variations in the structures, processes and outcomes of pharmacovigilance status among Asian countries.

Andrew Garrett spoke on a panel at the Financial Times Pharmaceutical & Biotechnology conference, about the recent integration of artificial intelligence (AI) enabled services in pharma R&D.

Ian O'Shaughnessy considers how to ensure a reality for the bright future of digitisation as clinical trials evolve.

David Novotny and Angela Brown outline how manufacturers can develop a strategic business model that will prepare them for success under new MDR/IVDR reforms.

This article featured in Forbes considers how technology – particularly AI and big data – can enable precision medicine.

A thought leadership article authored by Jenny Lee and Gene Chieh, investigating how biosimilars have gained momentum in a growing number of markets.

An interview with Nicole Cowan covering the new biomarker-driven landscape in clinical trials and the nuances of drug-diagnostics co-development programs.

ICON expert Gretchen Goller considers social media outreach's beneficial effect on patient connectivity to date in the October 2019 edition of PharmaVoice.